A Phase 1b/2a Open-Label Dose-Finding Followed by Randomized, Double-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TGD001 in Patients with Acute Ischemic Stroke

2025-522455-26-00 · tracked via the Priya Life Science EU tracker

Sponsor

TargED Biopharmaceuticals B.V.

Sponsor type

Pharmaceutical company

Therapeutic area

Nervous System Diseases

Decision date

31/10/2025

Enrollment target

Sites

Poland, Germany, Spain

Condition studied

Acute Ischemic Stroke

Investigational medicinal product(s)

SODIUM CHLORIDE SOLUTION 0.9%

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Symptomatic intracranial hemorrhage (sICH), Treatment emergent adverse events (TEAEs)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522455-26-00 on CTIS ↗ ← All trials in the EU